Opportunities to Improve Glaucoma Treatment
The goal of most glaucoma treatments is to lower eye pressure more effectively or more safely for longer periods of time.
A new molecular class of drugs, rho kinase (ROCK) inhibitors, is in development for the treatment of glaucoma patients. With minimal systemic side effects and tolerable ocular side effects, ROCK inhibitors have no contraindications - thus offering doctors and patients a necessary treatment option with convenient, once-a-day dosing.
Learn more about how this class fits into the timeline of advances in glaucoma treatment, and the potential that ROCK inhibitors may hold.
Read the Whitepaper now
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
